Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Alexander

Showing results (1081-1090 of 1,212) with videos related to

Pageof 122
Sort By:
EMBO Molecular Medicine|March 11, 2024
Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosaGrace Tartaglia, Ignacia Fuentes, Neil Patel, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS TrialJ H Alexander, H Yang, R C Becker, et al.
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
Nucleic Acids Research|November 18, 2017
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGYSimon D Harding, Joanna L Sharman, Elena Faccenda, et al.
Radiation Research|May 26, 2007
Retrospective biodosimetry among United States radiologic technologistsParveen Bhatti, Dale L Preston, Michele Morin Doody, et al.
Circulation|November 25, 2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)C Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
Journal of the American College of Cardiology|February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II TrialsJohn W Eikelboom, Hardi Mundl, John H Alexander, et al.
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
American Heart Journal|July 22, 2020
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart ValveOliver K Jawitz, Tracy Y Wang, Renato D Lopes, et al.
Journal of Cardiac Failure|July 21, 2023
Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical TrialsNathan P Goodwin, Robert M Clare, Josephine L Harrington, et al.
Pageof 122

Showing results (1081-1090 of 1,212) with videos related to

Sort By:
Pageof 122
EMBO Molecular Medicine|March 11, 2024
Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosaGrace Tartaglia, Ignacia Fuentes, Neil Patel, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS TrialJ H Alexander, H Yang, R C Becker, et al.
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
Nucleic Acids Research|November 18, 2017
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGYSimon D Harding, Joanna L Sharman, Elena Faccenda, et al.
Radiation Research|May 26, 2007
Retrospective biodosimetry among United States radiologic technologistsParveen Bhatti, Dale L Preston, Michele Morin Doody, et al.
Circulation|November 25, 2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)C Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
Journal of the American College of Cardiology|February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II TrialsJohn W Eikelboom, Hardi Mundl, John H Alexander, et al.
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
American Heart Journal|July 22, 2020
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart ValveOliver K Jawitz, Tracy Y Wang, Renato D Lopes, et al.
Journal of Cardiac Failure|July 21, 2023
Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical TrialsNathan P Goodwin, Robert M Clare, Josephine L Harrington, et al.
Pageof 122